Study management
RECRUITMENT
In July 2017, an interim analysis of 2 clinical trials in patients with treatment-naïve or R/R MM, KEYNOTE-18310 and KEYNOTE-185,11 demonstrated inferior overall survival (OS) of pembrolizumab plus Pom/Len vs the control arm (Dex plus Pom/Len), resulting in all studies evaluating anti-PD-(L)1 agents in combination with IMiDs (including GO29695) being placed on partial clinical hold in an FDA class action, despite no new safety signals being observed in this study. In November 2018, with no transformative benefits having been observed, a decision to terminate recruitment to GO29695 was made (patients on study with clinical benefit continued on treatment).